AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

When Insurance Barriers Become Life Threatening: A Preventable Cardiac Arrest in a 35-Year-Old with an Ultra-Rare Low-Density Lipoprotein Receptor Null Variant and Elevated Lipoprotein(a)

By Hassan R, Al-Abboud O, Tahir R

Background: Heterozygous familial hypercholesterolemia (HeFH) affects approximately 1 in 250 individuals and is most commonly caused by LDLR variants. With 2000 unique pathogenic variants, frameshift variants account for a particularly rare and severe phenotype. LDLR c.933delA (p.E312Sfs*58) is considered ultra-rare with no established prevalence data. Carriers of LDLR null variants have approximately 2-fold higher risk of MACE. Case: We present a 35-year-old male with HeFH on no lipid-lowering medications due to statin and evolocumab intolerance and payer denial of lipoprotein apheresis who presented with an out of hospital cardiac arrest. Two rounds of CPR were performed. Upon ROSC, patient was found to have an acute anterior STEMI. Patient underwent Impella assisted PCI with two DES to a 100% thrombotic occlusion of the proximal LAD. His course was complicated by refractory VT/VF and SCAI stage C cardiogenic shock, requiring Impella support, VA-ECMO, and milrinone. Lipid panel on hospital day 2 revealed total cholesterol 218 mg/dL, LDL-C 159 mg/dL, and TG 109 mg/dL. Post-discharge testing revealed lipoprotein(a) of 193 nmol/L. Post-arrest, echocardiogram showed LVEF 35% with hypokinesis to akinesis of the apical, anteroseptal, and anterior segments, with progressive recovery in subsequent echocardiograms. He also developed a right atrial thrombus along the Impella catheter requiring systemic anticoagulation and was discharged with a LifeVest. Post discharge, genetic testing revealed LDLR gene c.933delA (p.E312Sfs*58) consistent with monogenic HeFH. Patient was started on alirocumab and GDMT for HFrEF. At 1-month follow-up, echocardiography showed LVEF 50%, and the LifeVest was removed. Post-discharge testing revealed lipoprotein(a) of 193 nmol/L. Discussion: Untreated FH carries high premature coronary event risk i.e., up to 50% in men by age 50 and 30% in women by age 60. Monogenic FH carries approximately twice the cardiovascular risk of polygenic hypercholesterolemia at similar LDL-C levels. Notably, this patient also had a markedly elevated lipoprotein(a) of 193 nmol/L, an independent risk factor for ASCVD. Only 47% of PCSK9 inhibitor prescriptions are reported to be approved by payers. Lipoprotein apheresis may be limited by reimbursement variability with annual costs of $50,000-150,000, and prolonged preauthorization. These systemic barriers to evidence-based therapy can result in catastrophic cardiovascular events, as illustrated by this case with out-of-hospital cardiac arrest, anterior STEMI from 100% LAD occlusion, refractory VT/VF, cardiogenic shock requiring Impella and VA-ECMO, and RA thrombus. Conclusion: This case highlights the devastating consequences of delayed access to guideline-recommended lipid-lowering therapy in a young patient. Early recognition and aggressive lipid lowering in high-risk FH is not optional but lifesaving.

doi.org/10.1161/circ.154.suppl_1.19222Interventions

AgingResearch.News